T6445

Cilomilast (SB-207499) is a potent PDE4 inhibitor with an IC50 of approximately 110 nM, demonstrating anti-inflammatory activity and minimal central nervous system effects. Phase 3.

EST64454 is a σ1 receptor (σ1R) antagonist clinical candidate for the treatment of pain. EST64454 shows an outstanding aqueous solubility, which together with its high permeability in Caco-2 cells will allow its classification as a BCS class I compound. It also shows high metabolic stability.

EST64454 hydrochloride (EST64454) is a highly soluble σ1 receptor antagonist (Ki : 22 nM),has the potential for Pain Management.

EST64454 Maleic acid salt is the maleic acid salt form of EST64454.EST64454 is a highly soluble σ1 receptor antagonist clinical candidate for the treatment of pain.

Fmoc-Phe-Thr(psi(Me,Me)pro)-OH is an essential organic compound for life sciences research, catalog number T64451, CAS number 1196703-48-6.

4-Bromo-N-methylpicolinamide is a useful organic compound for research related to life sciences. The catalog number is T64454 and the CAS number is 1209459-88-0.

Magnesium citrate is a useful organic compound for research related to life sciences. The catalog number is T64455 and the CAS number is 3344-18-1.

Omilancor (BT-11) is a direct LANCL2 (Lanthionine Synthetase Cyclase-Like 2) activator with oral activity for the treatment of Crohn's Disease (CD), Inflammatory Bowel Disease (IBD) and Ulcerative Colitis (UC).

EHT-6706 is a novel microtubule-disrupting agent that targets the colchicine-binding site to inhibit tubulin polymerization. At low nM concentrations, EHT 6706 exhibits highly potent antiproliferative activity on more than 60 human tumor cell lines, even those described as being drug resistant. EHT 6706 also shows strong efficacy as a vascular-disrupting agent, since it prevents endothelial cell tube formation and disrupts pre-established vessels, changes the permeability of endothelial cell monolayers and inhibits endothelial cell migration. Genome-wide transcriptomic analysis of EHT 6706 effects on human endothelial cells shows that the antiangiogenic activity elicits gene deregulations of antiangiogenic pathways. These findings indicate that EHT 6706 is a promising tubulin-binding compound with potentially broad clinical antitumor efficacy.